483 Zhejiang Huahai Pharmaceutical Nov 2016

483 Zhejiang Huahai Pharmaceutical Nov 2016

Peter Baker FDA, Justin Boyd FDA$119.00 - Available Now

FDA investigators audited the Zhejiang Huahai Pharmaceutical - Taizhou, China facility and issued inspectional observation (via FDA 483) on 18 Nov 2016.

Product details

  • Category: Human Drugs
  • Inspection end: 18 Nov 2016
  • Location: Taizhou, China
  • FEI: 3003999190
Add To Cart